Google
QURE 株価分析 — Uniqure NV (Healthcare >> Biotechnology)
QURE に関するよくある質問
QUREのROE（自己資本利益率）は？
Uniqure NVのROEは-77.83%です。
QUREの配当利回りは？
Uniqure NVの配当利回りは0.00%です。
QUREの品質スコア（Quality Score）は？
当社のAIはQUREの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
QUREは今が買い時ですか？
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
QUREはどのセクターに属しますか？
Uniqure NVはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
QURE AI Analysis Summary
Our AI summary for QURE: Uniqure NV (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -77.83%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 44.06
Price
0.43
(0.99%)
Day Change
|
|
|---|
QURE, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 44.06 |
| PBV / Sector |
9.34 / 44,219.29
|
| Earning Per Share | -3.67 |
| PE / Sector |
N/A / 19.28
|
| PEG or PE/Growth / Sector |
N/A / 1.23
|
| Average 1M Daily Value |
60.95 M
|
| Average 1W Daily Value |
92.48 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:02:03 |
| Symbol | QURE |
| Name | UNIQURE NV |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 69.37 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,026.46 / 9,645.64 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP
Phone: 31 20 240 6000
Website: https://www.uniqure.com
Employees: 221
Sector: Healthcare >> Biotechnology
Description: uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
